在 CKD 中，依帕列净在中位数 2 年时减少了肾脏疾病的进展，无论主要肾脏疾病类型如何。
In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
机构信息
Chung-Ang University College of Medicine, Seoul, South Korea, and University of California, San Francisco, California, USA (J.H.H.).
University of California, San Francisco, California, USA (C.H.).
出版信息
Ann Intern Med. 2024 Apr;177(4):JC40. doi: 10.7326/J24-0020. Epub 2024 Apr 2.
DOI:10.7326/J24-0020
PMID:38560913
Abstract
EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.
摘要
EMPA-KIDNEY 协作组。《柳叶刀·糖尿病与内分泌学》。2024;12:51-60. 38061372.
Zotero 插件